Clioquinol - A Novel Copper-Dependent and Independent Proteasome Inhibitor

E-ISSN： 1873-5576|11|3|325-331

ISSN： 1568-0096

Source： Current Cancer Drug Targets, Vol.11, Iss.3, 2011-03, pp. : 325-331

Disclaimer: Any content in publications that violate the sovereignty, the constitution or regulations of the PRC is not accepted or approved by CNPIEC.

Previous Menu Next

Abstract

Related content

Clioquinol: a novel therapeutic approach to AD?

Inpharma, Vol. 1, Iss. 1421, 2004-01 ,pp. : 6-6

Adis International

Access to resources Recommend Favorite

Clioquinol: novel agent for Alzheimer's disease?

Inpharma, Vol. 1, Iss. 1353, 2002-01 ,pp. : 4-4

Adis International

Access to resources Recommend Favorite

Recent advances in proteasome inhibitor discovery

By Pevzner Yuri Metcalf Rainer Kantor Melanie Sagaro Desiree Daniel Kenyon

Expert Opinion on Drug Discovery, Vol. 8, Iss. 5, 2013-06 ,pp. : 537-568

Informa Healthcare

Access to resources Recommend Favorite

Proteasome inhibitor patents (2010 – present)

By Metcalf Rainer Scott Latanya M Daniel Kenyon G Dou Q Ping

Expert Opinion on Therapeutic Patents, Vol. 24, Iss. 4, 2014-04 ,pp. : 369-382

Informa Healthcare

Access to resources Recommend Favorite

The redox-active, anti-cancer drug Dp44mT inhibits T-cell activation and CD25 through a copper-dependent mechanism

By Kalinowski Danuta S. Jansson Patric J. Kovacevic Zaklina Richardson Des R.

Redox Report, Vol. 18, Iss. 2, 2013-03 ,pp. : 48-50

Maney Publishing

Access to resources Recommend Favorite